0001209191-23-033718.txt : 20230602 0001209191-23-033718.hdr.sgml : 20230602 20230602162339 ACCESSION NUMBER: 0001209191-23-033718 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230601 FILED AS OF DATE: 20230602 DATE AS OF CHANGE: 20230602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dunsire Deborah CENTRAL INDEX KEY: 0001332764 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37813 FILM NUMBER: 23989161 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001556263 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453772460 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-744-1340 MAIL ADDRESS: STREET 1: 35 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: LS22, Inc. DATE OF NAME CHANGE: 20120815 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-01 0 0001556263 Syros Pharmaceuticals, Inc. SYRS 0001332764 Dunsire Deborah C/O SYROS PHARMACEUTICALS, INC. 35 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 1 0 0 0 0 Stock Option (right to buy) 3.70 2023-06-01 4 A 0 6000 0.00 A 2033-05-31 Common Stock 6000 6000 D Restricted Stock Units 2023-06-01 4 A 0 4000 0.00 A Common Stock 4000 4000 D The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. These RSUs will vest in their entirety on the earlier to occur of (i) the first anniversary of the date of grant of the award, or (ii) the date of the Company's next Annual Meeting of Stockholders, subject in each case to the director's continued service as a director through the applicable vesting date. /s/ Todd Rosenthal, as attorney-in-fact 2023-06-02